As War On Cancer Hits 25-Year Mark, Scientists See Progress, Challenges

It's 25 years and counting since President Richard Nixon signed the National Cancer Act on Dec. 23, 1971, marking the United States' official declaration of war on cancer. The act provided funding to establish medical centers dedicated to clinical research and cancer treatment under the auspices of the National Cancer Institute (NCI). Yet, after an estimated $28 billion spent to find cures and better treatments for the dreaded disease, the war is far from over. Most scientists note the tremend

Written bySteven Benowitz
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

It's 25 years and counting since President Richard Nixon signed the National Cancer Act on Dec. 23, 1971, marking the United States' official declaration of war on cancer. The act provided funding to establish medical centers dedicated to clinical research and cancer treatment under the auspices of the National Cancer Institute (NCI). Yet, after an estimated $28 billion spent to find cures and better treatments for the dreaded disease, the war is far from over.

Most scientists note the tremendous strides made in treating -- and even curing -- some cancers -- particularly childhood leukemias and Hodgkin's disease. They point to new breakthroughs in understanding the molecular and genetic processes of the cancer cell. In addition, they note, patients now live longer and have a better quality of life. But critics invariably point to one inexorable fact: Cancer is on the rise and no abatement is in sight. The major ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies